Serving All Counties in California
(949) 250-0125 or Toll Free (877) 813-5582


Imagine a world without Alzheimers

Imagine a World without Alzheimer’s

As of today, Alzheimer’s and Dementia can’t be slowed, cured or prevented. Our friends at Syrentis Clinical Research and Dr. John Duffy are working to change that.

Syrentis Clinical Research and our friend Dr. John Duffy strive to better the lives of those affected by Alzheimer’s. By developing cutting edge treatments, they aim to achieve this and prevent memory loss due to the disease. The group specializes in studies associated with Alzheimer’s and is working tirelessly testing medical strategies. The dedicated staff has been conducting clinical trials in Orange County for over 15 years.

Progress in Alzheimer’s research has gained some real momentum over the last few years. A future without Alzheimer’s or Dementia is not so far fetched.

November is #AlzheimersAwarenessMonth. What better time than now, to learn more about the different FDA approved research studies working to #EndAlz!

The A4 Study

The main goal of the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 Study for short) is to prevent or slow memory loss.

The A4 study seeks older individuals (ages 65-85) who may be at risk for memory loss due to Alzheimer’s Disease. Eligible participants must have normal thinking and memory function and no outward signs of the disease to be considered for the study. See if you qualify!

At risk, older individuals with a first degree relative with Alzheimer’s have an increased likelihood of developing changes in the brain connected to the disease.

The TRIAD Research Study (Trial to Improve Agitation in Dementia)

Alzheimer’s has been known to cause anxiousness or agitation. Living with Alzheimer’s may make someone restless and feel the need to move around or pace. A person can easily able become upset when focused on specific details or engage in physical and verbal aggression when agitated. Agitation due to Alzheimer’s can be extremely disruptive and potentially harmful to you and your loved one.

The TRIAD Research Study is addressing agitation in Alzheimer’s and currently evaluating a new medication that may reduce symptoms of agitation due to Alzheimer’s disease.


Do you or a loved one suffer from any of these symptoms due to Alzheimer’s disease?

  • Always tense
  • Stressed
  • Exhausted
  • Overwhelmed
  • Worried
  • Nervous

To Qualify

  • Be between 50 and 90 years of age
  • Have a caregiver able to attend all study visits
  • Have moderate to sever agitation due to Alzheimer’s Disease

The EMERGE Study

Having memory problems?
Trouble thinking clearly?
Does this sound like you or someone you know? If so, please consider the EMERGE Study.

This is a global study assessing the effectiveness and safety of an investigational medication aimed at slowing the progression of symptoms in early Alzheimer’s Disease. Currently, there are no approved treatments to slow or delay the course of the condition. The study strictly focuses on medical and scientific research to delay memory loss and progression of the disability.


Emerge & Engage

  • Be between 50-85 years of age
  • Experienced symptoms that might be related to early Alzheimer’s disease such as
  • Daily problems with thinking or memory
  • Trouble remembering appointments
  • Forgetting the correct month or year
  • Trouble handling financial affairs (balancing a checkbook, paying bills, or income taxes)
  • Repeating the same things over and over

Alzheimer’s Steadfast Study

The Steadfast Study is the last phase of study for an investigational medicine believed to slow the progression of Alzheimer’s Disease. The medication, Azeliragon, works by blocking a receptor in the brain thought to contribute to many of the different causes of Alzheimer’s.


Do you qualify?

  • 50 years of age and diagnosed with mild Alzheimer’s
  • Already taking one or more of the following medications for at least 3 months prior

memantine (Namenda or Ebixa)
galantamine (Razadyne or Reminyl)

The Mindset Study

MINDSET is a Phase III clinical research program evaluating an investigational medication, RVT-101, for mild-to-moderate Alzheimer’s disease. Researchers are investigating how effective RVT-101 in combination with donepezil will be in helping with patients’ cognition and ability to perform daily living activities, as compared with donepezil alone.

To Qualify

  • Experiencing problems related to memory loss or have been diagnosed with Alzheimer’s or Dementia
  • 50 to 85 years of age
  • Taking donepezil
  • Accompanied by a caregiver or loved one who is willing to oversee the participant’s involvement in this clinical research study and provide information about how the participant is doing over the
  • study.

If you or an aging loved one sound qualified to participate in any of the trials, don’t hesitate to reach out today! Participation is completely voluntary, and often compensated for time and travel.

Join the fight to prevent memory loss associated with Alzheimer’s Disease.